And we have this white powder in front of me. You got a big smile on your face. >> I do because I don't care who you are, you should definitely be having this.Let's talk about creatine. Phenomenal research shows you can creatine your way out of sleep deprivation. It can protect your brain against a concussion, stroke, from stress.And there was a study done on Alzheimer's disease patients. And they found that patients not only preserved their cognitive functions, but they had more energy and they were able t ...

Core Insights - Anavex Life Sciences Corp. reported a peer-reviewed publication demonstrating that pre-treatment with blarcamesine can prevent cognitive decline and brain injury associated with Alzheimer's disease, indicating its potential as a pharmacological preventive treatment [2][3][6]. Company Overview - Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for various CNS disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia [2][10]. - The lead drug candidate, ANAVEX®2-73 (blarcamesine), has completed multiple clinical trials for Alzheimer's disease and other CNS disorders, showing potential to halt or reverse disease progression [10]. Research Findings - The study published in Neuroscience Letters indicates that blarcamesine prevents amyloid beta-induced memory impairment and oxidative injury in a preclinical model, suggesting its role in Alzheimer's disease prevention [2][3]. - Blarcamesine's mechanism involves the activation of SIGMAR1, which enhances autophagy and helps normalize amyloid-beta production, thereby restoring cellular homeostasis [4][5]. Market Context - Alzheimer's disease is a significant public health issue, with an estimated 7.2 million Americans currently affected and costs associated with the disease projected to rise from $781 billion in 2020 to $1.1 trillion by 2050 [8][9]. - The global prevalence of dementia is expected to increase from over 50 million currently to nearly 152 million by 2050, highlighting the urgent need for effective treatments [9].

Summary of New Amsterdam Pharma Company (NAMS) Conference Call - July 30, 2025 Company Overview - **Company**: New Amsterdam Pharma Company (NAMS) - **Focus**: Development of obacetropib for Alzheimer's disease and its potential as a disease-modifying therapy Key Industry Insights - **Alzheimer's Disease**: The conference highlighted the significance of obacetropib in potentially slowing or preventing Alzheimer's disease progression, particularly in APOE4 carriers, a high-risk genetic group for both Alzheimer's and cardiovascular diseases [6][7][9] - **Biomarkers**: The presentation emphasized the importance of pTau217 as a biomarker for Alzheimer's disease progression, showing that obacetropib significantly reduced pTau217 levels compared to placebo [12][13][14][18] Core Findings and Data - **Clinical Trial Results**: - In the Broadway trial, obacetropib resulted in a statistically significant reduction in pTau217 progression over 12 months, with a 1.99% increase in the treatment group versus nearly 5% in the placebo group (p=0.019) [12] - In APOE4 carriers, the increase was 1.45% with obacetropib compared to 7.19% with placebo (p=0.022) [12] - In APOE4 homozygotes, a 20.5% absolute difference in pTau217 progression was observed (p=0.01) [13] - **Comprehensive Biomarker Improvement**: The trial showed favorable trends across multiple Alzheimer's biomarkers, including GFAP and neurofilament light (NfL), indicating a potential for disease modification [15][22][24] Potential Market Impact - **Differentiation from Existing Therapies**: Obacetropib is positioned as a first-in-class oral therapy that not only lowers LDL cholesterol but also addresses Alzheimer's pathology, which is not achieved by current anti-amyloid therapies [22][25] - **Target Population**: Approximately 25% of the general population are APOE4 carriers, representing a significant market opportunity for obacetropib as a preventive treatment [23][36] Regulatory and Development Considerations - **Future Studies**: The company plans to engage with the FDA regarding the potential for obacetropib to be used in primary prevention of Alzheimer's disease, with ongoing trials like PREVAIL involving 9,500 patients [54][59] - **Biomarker as Endpoint**: There is ongoing discussion about the potential for pTau217 to be accepted as a registrational endpoint, although current FDA stance may require cognitive outcome data [63][70] Expert Panel Insights - **Panelists' Perspectives**: Experts highlighted the significance of the findings, particularly the safety profile of obacetropib and its potential for early intervention in high-risk populations [26][31][41] - **Preventive Neurology**: The need for a precision medicine approach in Alzheimer's treatment was emphasized, advocating for the use of biomarkers to personalize care [34][38] Conclusion - **Strategic Positioning**: New Amsterdam Pharma is positioned to lead in the development of innovative therapies for Alzheimer's disease, with obacetropib showing promise as a unique oral treatment that addresses both cardiovascular and neurodegenerative risks [22][25][54]

Core Insights - NewAmsterdam Pharma's obicetrapib significantly reduced plasma p-tau217 levels, a key Alzheimer's disease biomarker, in both the full analysis set and in ApoE4 carriers, indicating its potential as a novel approach to Alzheimer's prevention [1][3][13] - In ApoE4/E4 carriers, obicetrapib reduced p-tau217 levels by 20.5% over 12 months compared to placebo [1][4][5] - The results support obicetrapib's cardiometabolic profile, showing reductions in LDL-C and other cardiovascular risk factors [1][2][15] Company Overview - NewAmsterdam Pharma is a late-stage biopharmaceutical company focused on developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C [1][16] - The company aims to address unmet needs in populations where current therapies are inadequate or poorly tolerated [16] - Obicetrapib is being evaluated in multiple clinical trials, including the pivotal Phase 3 BROADWAY trial, which assesses its efficacy and safety in patients with established atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia [2][10][15] Clinical Trial Insights - The BROADWAY trial included 2,530 patients and was designed to evaluate the LDL-C lowering efficacy of obicetrapib [2][10] - A prespecified analysis of the trial assessed the effects of obicetrapib on plasma biomarkers of Alzheimer's disease in 1,515 patients, including 367 ApoE4 carriers [2][13] - The primary outcome measure was the absolute and percent change in p-tau217 over 12 months, with significant reductions observed [3][13] Biomarker Analysis - Statistically significant reductions in p-tau217 levels were observed in both the full analysis set and ApoE4 carriers, with p-values of 0.0019 and 0.0215, respectively [1][3][13] - Additional favorable trends were noted across other biomarkers, including NFL, GFAP, and p-tau181 [3][4][6] - The analysis highlights the potential of obicetrapib to influence Alzheimer's disease risk through lipid modulation, particularly in high-risk ApoE4 carriers [7][13] Future Directions - NewAmsterdam plans to discuss the results with regulatory authorities to determine potential next steps for obicetrapib [7][18] - The company is also exploring the commercialization rights of obicetrapib in Europe, which have been granted to the Menarini Group [15][16]

Core Insights - Obicetrapib significantly reduced plasma p-tau217 levels, a key Alzheimer's disease biomarker, in both the full analysis set and in ApoE4 carriers, indicating its potential as a novel approach to Alzheimer's prevention [1][3][12] - In ApoE4/E4 carriers, obicetrapib reduced p-tau217 levels by 20.5% over 12 months compared to placebo [1][4] - The results support obicetrapib's cardiometabolic profile, showing reductions in LDL-C and other cardiovascular risk factors [1][2] Company Overview - NewAmsterdam Pharma is a late-stage biopharmaceutical company focused on developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C [1][15] - The company aims to address unmet needs in populations where existing therapies are not sufficiently effective or well-tolerated [15] Clinical Trial Details - The BROADWAY trial was a pivotal Phase 3 study designed to evaluate the LDL-C lowering efficacy of obicetrapib in patients with established atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia [2][10] - A total of 2,530 patients were randomized to receive either 10 mg obicetrapib or placebo for 52 weeks, with the primary endpoint being the percent change in LDL-C [10][11] Biomarker Analysis - The prespecified analysis evaluated the effect of obicetrapib on plasma biomarkers of Alzheimer's disease in 1,515 patients, including 367 ApoE4 carriers [2][12] - Statistically significant reductions in p-tau217 were observed, with additional favorable trends in other biomarkers such as NFL and GFAP [3][4][12] Implications for Alzheimer's Disease - The findings suggest that upstream lipid modulation may influence Alzheimer's disease risk, particularly in ApoE4 carriers, who represent over 25% of the population [7] - Obicetrapib's ability to reduce multiple important AD biomarkers alongside its LDL-C lowering effects highlights its potential to address both neurodegenerative and cardiovascular disease risks [7][14]

Financial Data and Key Metrics Changes - The company is executing a Fit for Growth program aimed at optimizing its cost structure, with a target of achieving $800 million in net cost savings by the end of the year [44] - The company has successfully executed activities necessary to yield $1 billion in growth and $800 million in net savings [44] Business Line Data and Key Metrics Changes - The company has shifted its focus from primarily neuroscience to include immunology and nephrology, with significant investments in four ongoing product launches [4][9] - The company has nine programs in phase three or phase three ready, indicating a robust pipeline for future growth [7] Market Data and Key Metrics Changes - The U.S. launch of Skyclaris is in a steady growth phase, while initial launches in Europe are progressing similarly [48] - The company has received approval in Brazil for Skyclaris, which is expected to be an important market [49] Company Strategy and Development Direction - The company is focused on redeploying capital from its MS business to support new growth opportunities in nephrology and immunology [5] - The company is actively pursuing business development opportunities, including the acquisition of Hai Bio, to enhance its pipeline [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the foundational position of the company for future capital deployment and growth opportunities [6] - The company is monitoring potential changes in drug pricing policies and tariffs, which could impact negotiations in the EU [14][15] Other Important Information - The company is excited about the potential of its pipeline assets, particularly in rare diseases and kidney diseases, as highlighted in an upcoming investor presentation [40][41] - The company is leveraging AI technology to identify patients for its therapies, indicating a focus on innovative approaches in patient engagement [49] Q&A Session Summary Question: How is the firm balanced now in terms of various disease areas? - The company is leveraging existing expertise in rare diseases while expanding into nephrology and immunology through strategic acquisitions [10] Question: What is the comfort level among PCP providers with the use of blood-based biomarker tests for Alzheimer's? - PCP providers are already using blood-based biomarkers alongside PET scans, indicating a growing acceptance of these tests [26] Question: What are the expectations for the upcoming readouts from the company's trials? - The company anticipates steady progression in growth and is optimistic about the potential for inflection points with new diagnostic tests and treatment methods [27]

Core Insights - NewAmsterdam Pharma announced positive topline data from the Phase 3 BROADWAY clinical trial, indicating that obicetrapib treatment leads to significant reductions in Alzheimer's disease biomarkers in both the full population and ApoE4 carriers [1][2][3] Group 1: Clinical Trial Details - The BROADWAY study was designed to evaluate the LDL-C lowering efficacy of obicetrapib in patients with established atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH) [2][4] - The trial involved 2,530 patients randomized to receive either 10 mg obicetrapib or placebo for 52 weeks, with a mean baseline LDL-C of approximately 100 mg/dL [4][5] - The primary endpoint showed a 33% reduction in LDL-C after 84 days for the obicetrapib group compared to placebo [6] Group 2: Alzheimer's Disease Sub-Study - A pre-specified sub-study assessed the effects of obicetrapib on plasma biomarkers of Alzheimer's disease, including p-tau217, in 1,727 patients, with significant results in both the full population (p<0.002) and ApoE4 carriers (p=0.0215) [7] - The sub-study aimed to evaluate the impact of a 12-month therapy duration on AD biomarkers, indicating a potential to alter disease trajectory in ApoE4 carriers [3][7] Group 3: Implications and Future Plans - The findings suggest a potential preventive strategy for Alzheimer's disease, particularly for the 25% of the population carrying ApoE4 risk alleles [3] - NewAmsterdam plans to present full results from the AD sub-study at the Alzheimer's Association International Conference in July 2025 [1][3] Group 4: About Obicetrapib - Obicetrapib is a novel, oral, low-dose CETP inhibitor developed to address limitations of current LDL-lowering treatments, showing significant LDL-lowering effects in multiple trials [9][10] - The company has also initiated the Phase 3 PREVAIL cardiovascular outcomes trial, which has enrolled over 9,500 patients [9]